Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors.

Stevens KL, Alligood KJ, Alberti JG, Caferro TR, Chamberlain SD, Dickerson SH, Dickson HD, Emerson HK, Griffin RJ, Hubbard RD, Keith BR, Mullin RJ, Petrov KG, Gerding RM, Reno MJ, Rheault TR, Rusnak DW, Sammond DM, Smith SC, Uehling DE, Waterson AG, Wood ER.

Bioorg Med Chem Lett. 2009 Jan 1;19(1):21-6. doi: 10.1016/j.bmcl.2008.11.023. Epub 2008 Nov 13.

PMID:
19028424
2.

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ.

Cancer Res. 2006 Feb 1;66(3):1630-9.

3.
4.

Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines.

Gaul MD, Guo Y, Affleck K, Cockerill GS, Gilmer TM, Griffin RJ, Guntrip S, Keith BR, Knight WB, Mullin RJ, Murray DM, Rusnak DW, Smith K, Tadepalli S, Wood ER, Lackey K.

Bioorg Med Chem Lett. 2003 Feb 24;13(4):637-40.

PMID:
12639547
5.

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM.

Mol Cancer Ther. 2001 Dec;1(2):85-94.

6.

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.

Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL.

Oncogene. 2002 Sep 12;21(41):6255-63.

7.

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, Jowett A, Stables J, Topley P, Wood ER, Brignola PS, Kadwell SH, Reep BR, Mullin RJ, Alligood KJ, Keith BR, Crosby RM, Murray DM, Knight WB, Gilmer TM, Lackey K.

Cancer Res. 2001 Oct 1;61(19):7196-203.

8.

Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.

Wolfe LA, Mullin RJ, Laethem R, Blumenkopf TA, Cory M, Miller JF, Keith BR, Humphreys J, Smith GK.

Bioconjug Chem. 1999 Jan-Feb;10(1):38-48.

PMID:
9893962
9.

Screening for child-reported behavioral and emotional problems in primary care pediatrics.

Merritt KA, Thompson RJ Jr, Keith BR, Gustafson KE, Murphy LB, Johndrow DA.

Percept Mot Skills. 1995 Feb;80(1):323-9.

PMID:
7624213
10.

Psychological adjustment of children with sickle cell disease: stability and change over a 10-month period.

Thompson RJ Jr, Gil KM, Keith BR, Gustafson KE, George LK, Kinney TR.

J Consult Clin Psychol. 1994 Aug;62(4):856-6.

PMID:
7962891
11.

Stability and change in the psychological adjustment of mothers of children and adolescents with cystic fibrosis and sickle cell disease.

Thompson RJ Jr, Gil KM, Gustafson KE, George LK, Keith BR, Spock A, Kinney TR.

J Pediatr Psychol. 1994 Apr;19(2):171-88.

PMID:
8051601
12.

Sickle cell disease pain in children and adolescents: change in pain frequency and coping strategies over time.

Gil KM, Thompson RJ Jr, Keith BR, Tota-Faucette M, Noll S, Kinney TR.

J Pediatr Psychol. 1993 Oct;18(5):621-37.

PMID:
8295083
13.

Psychological adjustment of mothers of children and adolescents with sickle cell disease: the role of stress, coping methods, and family functioning.

Thompson RJ Jr, Gil KM, Burbach DJ, Keith BR, Kinney TR.

J Pediatr Psychol. 1993 Oct;18(5):549-59.

PMID:
8295079
14.

Screening for behavioral and emotional problems in primary care pediatrics.

Merritt KA, Thompson RJ Jr, Keith BR, Johndrow DA, Murphy LB.

J Dev Behav Pediatr. 1993 Oct;14(5):340-3.

PMID:
8254066
15.

Mother-child agreement on the child assessment schedule with nonreferred children: a research note.

Thompson RJ Jr, Merritt KA, Keith BR, Murphy LB, Johndrow DA.

J Child Psychol Psychiatry. 1993 Jul;34(5):813-20.

PMID:
8340447
16.

Role of child and maternal processes in the psychological adjustment of children with sickle cell disease.

Thompson RJ Jr, Gil KM, Burbach DJ, Keith BR, Kinney TR.

J Consult Clin Psychol. 1993 Jun;61(3):468-74.

PMID:
8326049
17.

The Missouri Children's Behavior Checklist behavioral classification system: a construct validity study with nonreferred children.

Thompson RJ Jr, Merritt KA, Keith BR, Murphy LB, Johndrow DA.

J Clin Psychol. 1992 Nov;48(6):739-43.

PMID:
1452762
18.

In vivo antitumor activity and metabolism of a series of 5-deazaacyclotetrahydrofolate (5-DACTHF) analogues.

Mullin RJ, Keith BR, Bigham EC, Duch DS, Ferone R, Heath LS, Singer S, Waters KA, Wilson HR.

Biochem Pharmacol. 1992 Apr 1;43(7):1627-34.

PMID:
1567484
19.

Effect of type 1 piliation on in vitro killing of Escherichia coli by mouse peritoneal macrophages.

Keith BR, Harris SL, Russell PW, Orndorff PE.

Infect Immun. 1990 Oct;58(10):3448-54.

20.

In vivo and in vitro metabolism of 5-deazaacyclotetrahydrofolate, an acyclic tetrahydrofolate analogue.

Hanlon MH, Ferone R, Mullin RJ, Keith BR.

Cancer Res. 1990 Jun 1;50(11):3207-11.

21.
22.

Distribution and metabolism of calcium leucovorin in normal and tumor tissue.

Mullin RJ, Keith BR, Duch DS.

Adv Exp Med Biol. 1988;244:25-38. No abstract available.

PMID:
3266825
23.

Comparison of response formats for Multidimensional Health Locus of Control Scales: six levels versus two levels.

McCallum DM, Keith BR, Wiebe DJ.

J Pers Assess. 1988 Winter;52(4):732-6.

PMID:
3210135
24.
25.

Supplemental Content

Loading ...
Support Center